Check-Cap (NASDAQ:CHEK) Research Coverage Started at StockNews.com

StockNews.com started coverage on shares of Check-Cap (NASDAQ:CHEK) in a research note issued to investors on Tuesday morning. The firm issued a sell rating on the medical research company’s stock.

Check-Cap Price Performance

NASDAQ CHEK opened at $2.29 on Tuesday. Check-Cap has a 1 year low of $1.27 and a 1 year high of $4.63. The stock has a market capitalization of $13.37 million, a PE ratio of -0.76 and a beta of 0.28. The company’s 50 day simple moving average is $2.26 and its two-hundred day simple moving average is $2.56.

Check-Cap Company Profile

Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based screening technology that utilizes ultra-low-dose X-rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule for detection of suspected polyps; C-Scan Track, a disposable system attached to the patient's back through biocompatible adhesive skin patches; and C-Scan View software, a client/server-based application that enables procedure data download from the C-Scan Track, data analysis, and report generation.